使用生理药代动力学模型预测不同叶酸剂量对[68Ga]Ga-PSMA-11器官与肿瘤摄取的影响
本研究建立[68Ga]Ga-PSMA-11与叶酸的生理药代动力学(PBPK)模型,用两项研究的患者扫描数据及文献叶酸数据评估模型,并模拟不同叶酸剂量对唾液腺、肾脏和肿瘤摄取的影响。模拟显示5 mg和10 mg叶酸使唾液腺与肾脏摄取出现临床相关下降,而150 µg 5-MTHF与400 µg叶酸无临床相关影响,各剂量下肿瘤摄取均未受明显影响。
要点
- 模拟显示5 mg叶酸使唾液腺摄取下降34%、肾脏下降32%,10 mg分别下降36%与34%。
- 150 µg 5-MTHF与400 µg叶酸在t=0给药时对唾液腺和肾脏摄取无临床相关影响。
- 模拟剂量范围内(150 µg–10 mg)肿瘤摄取均未受叶酸给药明显影响。
核心结论
- PBPK模型预测高剂量叶酸(5 mg和10 mg)使[68Ga]Ga-PSMA-11唾液腺与肾脏摄取下降,而含叶酸食物或维生素补充剂摄入无相关影响。
- 模拟剂量范围(150 µg–10 mg)内肿瘤摄取未受叶酸给药影响,肿瘤体积差异预计不影响叶酸对[68Ga]Ga-PSMA-11器官摄取的作用。
研究设计与样本
- 开发针对[68Ga]Ga-PSMA-11与叶酸(叶酸及其代谢物5-MTHF)的PBPK模型,并添加代表唾液腺和肿瘤的隔室。
- 模型包含受体结合、内化与细胞内降解反应;[68Ga]Ga-PSMA-11模型评估使用两项不同研究(静态与动态)的患者扫描数据,叶酸模型评估使用文献数据。
- 模拟评估不同叶酸剂量(150 µg、400 µg、5 mg和10 mg)对唾液腺、肾脏和肿瘤蓄积的影响,并涵盖不同肿瘤体积(10、100、500和1000 mL)的患者。
主要发现
- 最终模型评估显示预测充分描述了[68Ga]Ga-PSMA-11与叶酸的数据。
- 预测5-MTHF 150 µg与叶酸400 µg(与[68Ga]Ga-PSMA-11同时给药(t=0)时)对唾液腺和肾脏摄取无临床相关影响。
- 预测5 mg剂量使唾液腺摄取下降34%、肾脏下降32%,10 mg剂量使唾液腺下降36%、肾脏下降34%,判定为临床相关。
- 预测所有不同叶酸剂量(范围150 µg–10 mg)下肿瘤摄取均未受叶酸共同给药的相关影响。
- 不同肿瘤体积不影响叶酸对[68Ga]Ga-PSMA-11生物分布的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Folate intake might reduce [68Ga]Ga-PSMA-11 uptake in tissues due to a competitive binding to the PSMA receptor. For diagnostic imaging, this could impact decision making, while during radioligand therapy this could affect treatment efficacy. The relationship between folate dose, timing of dosing and tumor and organ uptake is not well established. The aim of this study was to develop a physiologically based pharmacokinetic (PBPK) model to predict the effect of folates on [68Ga]Ga-PSMA-11 PET/CT uptake in salivary glands, kidneys and tumors. METHODS: A PBPK model was developed for [68Ga]Ga-PSMA-11 and folates (folic acid and its metabolite 5-MTHF), with compartments added that represent salivary glands and tumor. Reactions describing receptor binding, internalization and intracellular degradation were included. Model evaluation for [68Ga]Ga-PSMA-11 was performed by using patient scan data from two different studies (static and dynamic), while for folates data from the literature were used for evaluation. Simulations were performed to assess the effect of different folate doses (150 µg, 400 µg, 5 mg and 10 mg) on accumulation in salivary glands, kidney and tumor, also for patients with different tumor volumes (10, 100, 500 and 1000 mL). RESULTS: Final model evaluation showed that predictions adequately described data for both [68Ga]Ga-PSMA-11 and folates. Predictions of a 5-MTFH dose of 150 µg and folic acid dose of 400 µg (in case of administration at the same time as [68Ga]Ga-PSMA-11 (t = 0)) showed no clinically relevant effect on salivary glands and kidney uptake. However, the effect of a decrease in salivary glands and kidney uptake was determined to be clinically relevant for doses of 5 mg (34% decrease for salivary glands and 32% decrease for kidney) and 10 mg (36% decrease for salivary glands and 34% decrease for kidney). Predictions showed that tumor uptake was not relevantly affected by the co-administration of folate for all different folate doses (range 150 µg-10 mg). Lastly, different tumor volumes did not impact the folate effect on [68Ga]Ga-PSMA-11 biodistribution. CONCLUSION: Using a PBPK model approach, high doses of folate (5 and 10 mg) were predicted to show a decrease of [68Ga]Ga-PSMA-11 salivary glands and kidney uptake, while intake by means of folate containing food or vitamin supplements showed no relevant effects. In addition, tumor uptake was not affected by folate administration in the simulated dose ranges (150 µg-10 mg). Differences in tumor volume are not expected to impact folate effects on [68Ga]Ga-PSMA-11 organ uptake.
引用
- Siebinga H, Hendrikx JJMA, Huitema ADR, et al. Predicting the effect of different folate doses on [68Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling. EJNMMI Res. 2023. PMID: 37318681. doi:10.1186/s13550-023-01008-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。